Theranostics and how it works

Theranostics is a personalised treatment combining diagnostics and therapies to detect and treat a range of cancers.1

Make an enquiry

Theranostics

Make an enquiry about theranostics

Contact our theranostics team directly to find out how we can help you.

08 9438 8500
08 9438 8500

Theranostics is a developing new approach to cancer treatment which may be suitable for some patients who have not responded to other therapies or who have complex metastases (e.g. where cancer has spread to multiple sites).

Based on current research and clinical experiences, it is most likely to be suitable for patients with metastatic prostate cancer and neuroendocrine tumours.1,2 Your GenesisCare oncologist will determine if theranostics may be suitable for you.

How it works

Theranostics is a personalised approach to treating cancer, using both diagnosis and therapy tools as part of the treatment. Theranostics uses PET scan imaging (a special type of scan) to see if specific targets, known as tumour receptors, are present on tumour cells.

If these targets are present and visible on the scan, a radioactive drug is used to treat the tumours. The drug is given as an injection and selectively targets the tumour cells while avoiding healthy areas.1,2 Most of the radioactive drug that doesn’t reach the target is quickly passed out of the body.

/content/dam/asset-migration/graphics/au/AU_Oncology_Theranostics_Graphic_GA.png

Theranostics treatment involves one or more therapeutic goods which have not been reviewed for safety, quality, or efficacy by the Therapeutic Goods Administration (TGA). Some patients may be eligible to access this treatment under the Special Access Scheme. The cost of treatment may be an out-of-pocket expense.3

Theranostics patient journey

It is important that you feel informed and supported on your Theranostics treatment journey. We are here to answer any questions or concerns you may have. Here are questions that others often ask:

Where is theranostics offered?

We currently have five centres in Australia offering theranostics treatment for suitable patients.

Make an enquiry about theranostics

Contact our theranostics team directly to find out how we can help you.

08 9438 8500
08 9438 8500

Our partnerships

For enquiries regarding partnership opportunities, please contact us via theranosticsreception@genesiscare.com.au

Our theranostic specialists

Prof Nat Lenzo

BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD

Nuclear Medicine Physician

Hurstville (Oncology) +1

Dr Brett Sounness

BSc, MBBS, FRANZCR, FAANMS

Nuclear Medicine Physician

Dr Geoffrey Schembri

MBBS, BSC(MED), DDU, FRACP, FAANMS

Nuclear Medicine Physician

North Shore

A/Prof Paul Roach

MBBS (HONS), FRACP, FAANMS

Nuclear Medicine Physician

Dr Elizabeth Bernard

MBBS Honours FRACP, FAANMS

Nuclear Medicine Physician

North Shore

Dr Jeremy Hoang

MBBS (SYD), FRACP, FAANMS, DDU

Nuclear Medicine Physician

North Shore

Dr Sharon Hain

MBBS, FRACP, BSc, FAANMS

Nuclear Medicine Physician

North Shore

Dr David Chan

MBBS, FRACP, BSc

Medical Oncologist

North Shore

Dr Laurence Krieger

MBChB (Hons) FRACP

Medical Oncologist

North Shore

References

  1. Gomes Marin JF, Nunes RF, Coutinho AM, et al. Theranostics in Nuclear Medicine- Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics. 2020;40(6)-1715-1740.
  2. Vu TM, Loveday BPT, Behrenbruch C, Hollande F, Heriot AG. Theranostics- a fifth pillar of contemporary cancer care? ANZ J Surg. 2022;92(11)-2782-2783.
  3. Therapeutic Goods Administration. Special Access Scheme: Guidance for health practitioners accessing unapproved therapeutic goods. V1.0 January 2023.

Disclaimer

Any medical procedure or treatment involving the use of radiation carries risks, including skin irritation and associated pain. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.